Back to Results

Anbio Biotechnology (NNNN)

Anbio Biotechnology (NNNN) is a NASDAQ-listed healthcare company in the biotechnology industry. This overview describes the security as common stock and reflects the common equity of Anbio Biotechnology rather than a fund, bond, or other instrument. Based on the provided context, the business is associated with diagnostic testing and related laboratory tools used in clinical and point-of-care settings. Its activities are presented at a broad level, without assuming additional operating details. For investors and market readers, the listing indicates an ordinary equity security tied to the company’s shares on NASDAQ.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-NNNN
$5.06
-3.7% Downside
Fair
Not available
Not available
Good
0.0%
36.0x
7.6x
26.6x
230.4 M
218.5 M
0.0%
90.4%
374.1
-105.2%
Valuation • Fair Value

Anbio Biotechnology (NASDAQ-NNNN) Fair Value by Valuation Model

Review the available estimates for Anbio Biotechnology (NASDAQ-NNNN), including DCF Fair Value, Ben Graham Formula Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$5.06

Estimated downside of 3.7% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$4.05

Discounted cash flow valuation reference.

Ben Graham Formula Value

$1.62

Classic Ben Graham valuation formula reference.

Comps Fair Value

$5.86

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 5 available valuation references for Anbio Biotechnology (NASDAQ-NNNN) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Anbio Biotechnology (NASDAQ-NNNN)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

8.647 M

Current operating scale indicator.

Revenue Forecast

8.949 M

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

EBITDA Forecast

4.184 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Anbio Biotechnology (NASDAQ-NNNN) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Anbio Biotechnology (NASDAQ-NNNN)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Altman Z-Score

374.1

Relatively strong balance-sheet zone.

FCF / Net Income

-105.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Anbio Biotechnology (NASDAQ-NNNN). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Anbio Biotechnology (NASDAQ-NNNN)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Anbio Biotechnology (NASDAQ-NNNN). No upcoming dividend amount or event date is currently available.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Anbio Biotechnology (NASDAQ-NNNN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Anbio Biotechnology (NASDAQ-NNNN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Anbio Biotechnology (NASDAQ-NNNN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Anbio Biotechnology (NASDAQ-NNNN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Anbio Biotechnology (NASDAQ-NNNN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Anbio Biotechnology (NASDAQ-NNNN) Stock FAQ

Data-supported answers about Anbio Biotechnology (NASDAQ-NNNN), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$5.06
Estimated downside 3.7%
Valuation Rating
Overvalued
Estimated downside of 3.7%
Financial Health
Good
Current financial-health read

The current fair value estimate for Anbio Biotechnology (NASDAQ-NNNN) is $5.06. This implies an estimated downside of 3.7% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 3.7% versus the current market price.

The current financial health read for Anbio Biotechnology (NASDAQ-NNNN) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Anbio Biotechnology (NASDAQ-NNNN).

The current P/E ratio listed for Anbio Biotechnology (NASDAQ-NNNN) is 36.0x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Anbio Biotechnology is 230.4 M.

The current enterprise value listed for Anbio Biotechnology is 218.5 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Anbio Biotechnology is NASDAQ-NNNN, and the stock is listed on NASDAQ.

Anbio Biotechnology (NASDAQ-NNNN) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Anbio Biotechnology is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Anbio Biotechnology is 90.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 466.4 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 208.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 186 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 128.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 78.353 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 62.595 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 61.522 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 53.245 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 40.928 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.9 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.055 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.841 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 28.748 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.206 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.4 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.131 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.214 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.546 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.864 B